Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.56 |
| ▸ | POLB | P06746 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.43 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2018241 | 0.81 | GAA (0.56) | KDM4EHTTHSD17B10MEN1KMT2A | |
| SCHEMBL10840553 | 0.81 | KDM4E (0.78) | KDM4EPOLBHTTHSD17B10MEN1 | |
| SCHEMBL10840421 | 0.81 | PLA2G2A (0.62) | KDM4EPOLBMEN1KMT2AGAA | |
| SCHEMBL12874096 | 0.78 | POLB (0.82) | KDM4EPOLBHTTHSD17B10MEN1 | |
| SCHEMBL2969551 | 0.77 | KDM4E (0.54) | KDM4EPOLBHSD17B10MEN1KMT2A | |
| SCHEMBL13078121 | 0.75 | SMN1; SMN2 (0.42) | KDM4EPOLBHTTHSD17B10MEN1 | |
| SCHEMBL2977504 | 0.73 | PPARG (0.45) | KDM4EMAPT | |
| SCHEMBL2978448 | 0.73 | MAPT (0.53) | POLBMEN1KMT2AGAAMAPT | |
| SCHEMBL31693313 | 0.70 | GAA (0.72) | KDM4EMEN1KMT2AGAAMAPT | |
| SCHEMBL2982065 | 0.69 | MAPT (0.44) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960427-B2 | Antivirals against Hepatitis B, HIV, and influenza viruses; e.g. ethyl 2-[(benzo[d]imidazol-2-yl)thiomethyl]-6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-1H-indole-3-carboxylate | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2011-06-14 | — | — | US | disclosed |
| US-20080249155-A1 | 5-Hydroxyindole-3-Carboxylate Derivatives and Uses Thereof | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2008-10-09 | — | — | US | disclosed |
| EP-1731506-A1 | 5-HYDROXYINDOLE-3-CARBOXYLATES DERIVATIVES AND THEIR USE | Shenyang Pharmaceutical University (CN) | 2006-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249155-A1 | 5-Hydroxyindole-3-Carboxylate Derivatives and Uses Thereof | TPH1, HTR3C, IDO1 | KDM4E 1867/4885POLB 2156/4885HTT 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.